Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2024; 15(2): 317-328
Published online Feb 24, 2024. doi: 10.5306/wjco.v15.i2.317
Limonin inhibits the stemness of cancer stem-like cells derived from colorectal carcinoma cells potentially via blocking STAT3 signaling
Wei-Feng Zhang, Cheng-Wei Ruan, Jun-Bo Wu, Guo-Liang Wu, Xiao-Gan Wang, Hong-Jin Chen
Wei-Feng Zhang, Jun-Bo Wu, Xiao-Gan Wang, Hong-Jin Chen, Department of Colorectal Surgery, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China
Wei-Feng Zhang, Cheng-Wei Ruan, Department of Anorectal Section, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China
Jun-Bo Wu, Department of Colorectal Surgery, Hengyang Central Hospital, Hengyang 421000, Hunan Province, China
Guo-Liang Wu, The First College for Clinical Medicine, Nanjing University Of Chinese Medicine, Nanjing 210023, Jiangsu Province, China
Author contributions: Zhang WF and Chen HJ are responsible for this project and designed experiments; Zhang WF, Ruan CW and Wu JB are responsible for performing experiments; Wu GL and Wang XG are responsible for data collection and data analysis; Zhang WF and Chen HJ are responsible for manuscript writing; All authors were aware of this manuscript.
Institutional animal care and use committee statement: All the animal experiments were conducted according to the Animal ethics committee in Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, No. 2019 DW-13-02. All mouse models were housed in the SPF animal facilities (temperature 21–25 °C; humidity 50%–60%; well-ventilated cages).
Conflict-of-interest statement: No conflicts of interest was declared.
Data sharing statement: All data generated or analysed during this study are included in this published article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Jin Chen, MD, Chief Doctor, Doctor, Full Professor, Department of Colorectal Surgery, The Affiliated Hospital of Nanjing University of Chinese Medicine, Hanzhong No. 155 Road, Nanjing 210029, Jiangsu Province, China. 260789@njucm.edu.cn
Received: October 9, 2023
Peer-review started: October 9, 2023
First decision: November 23, 2023
Revised: December 6, 2023
Accepted: January 8, 2024
Article in press: January 8, 2024
Published online: February 24, 2024
Core Tip

Core Tip: Colorectal cancer (CRC) is recognized worldwide as one of the most common malignancies and frequently leads to cancer-related death and the subpopulation termed cancer stem-like cell contributes critically to recurrence and metastasis. However, therapeutic molecule or strategy targeting to this subpopulation is still largely unknown. Here, we introduce Limonin, is one of the most abundant active ingredients of Tetradium ruticarpum, as a promising molecule targeting to cancer stem-like cells for CRC therapy.